相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Intratumoral administration of pro-inflammatory allogeneic dendritic cells improved the anti-turnor response of systemic anti-CTLA-4 treatment via unleashing a T cell-dependent response
Chuan Jin et al.
ONCOIMMUNOLOGY (2022)
The influence of testosterone suppression on HER2 immunoexpression in prostatic neoplastic tissue
Guilherme Andrade Peixoto et al.
MOLECULAR AND CLINICAL ONCOLOGY (2021)
Interleukin-8: A chemokine at the intersection of cancer plasticity, angiogenesis, and immune suppression
Kristen Fousek et al.
PHARMACOLOGY & THERAPEUTICS (2021)
Novel Combinatorial Approaches to Tackle the Immunosuppressive Microenvironment of Prostate Cancer
Erin G. Shackleton et al.
CANCERS (2021)
Kickstarting Immunity in Cold Tumours: Localised Tumour Therapy Combinations With Immune Checkpoint Blockade
Elizabeth Appleton et al.
FRONTIERS IN IMMUNOLOGY (2021)
Castration-mediated IL-8 promotes myeloid infiltration and prostate cancer progression
Zoila A. Lopez-Bujanda et al.
NATURE CANCER (2021)
Elevated serum interleukin-8 is associated with enhanced intratumor neutrophils and reduced clinical benefit of immune-checkpoint inhibitors
Kurt A. Schalper et al.
NATURE MEDICINE (2020)
Regulation of PD-L1 Expression by NF-κB in Cancer
Fabrizio Antonangeli et al.
FRONTIERS IN IMMUNOLOGY (2020)
Transforming Growth Factor-β Signaling in Immunity and Cancer
Eduard Batlle et al.
IMMUNITY (2019)
Cancer immunotherapy using checkpoint blockade
Antoni Ribas et al.
SCIENCE (2018)
NF-κB c-Rel Is Crucial for the Regulatory T Cell Immune Checkpoint in Cancer
Yenkel Grinberg-Bleyer et al.
CELL (2017)
MHC class II tetramer analyses in AE37-vaccinated prostate cancer patients reveal vaccine-specific polyfunctional and long-lasting CD4+ T-cells
Eleftheria A. Anastasopoulou et al.
ONCOIMMUNOLOGY (2016)
Unraveling the role of preexisting immunity in prostate cancer patients vaccinated with a HER-2/neu hybrid peptide
Ioannis F. Voutsas et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2016)
Personalized Peptide Vaccine for Treatment of Advanced Cancer
Tetsuro Sasada et al.
CURRENT MEDICINAL CHEMISTRY (2014)
Immunostimulatory monoclonal antibodies in cancer therapy
Fernando Aranda et al.
ONCOIMMUNOLOGY (2014)
Personalized peptide vaccination: a new approach for advanced cancer as therapeutic cancer vaccine
Masanori Noguchi et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2013)
Mechanism of Action of Conventional and Targeted Anticancer Therapies: Reinstating Immunosurveillance
Laurence Zitvogel et al.
IMMUNITY (2013)
HER-2/neu Expression in Prostate Adenocarcinoma: A Systematic Review and Meta-Analysis
Ary Serpa Neto et al.
JOURNAL OF UROLOGY (2010)
Her2 activates NF-κB and induces invasion through the canonical pathway involving IKKα
E. C. Merkhofer et al.
ONCOGENE (2010)
HER-2/neu mediated down-regulation of MHC class I antigen processing prevents CTL-mediated tumor recognition upon DNA vaccination in HLA-A2 transgenic mice
Simona Vertuani et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2009)
NF-κB-Mediated HER2 Overexpression in Radiation-Adaptive Resistance
Ning Cao et al.
RADIATION RESEARCH (2009)
Elevated levels of HER-2/neu and androgen receptor in clinically localized prostate cancer identifies metastatic potential
Carmela Ricciardelli et al.
PROSTATE (2008)
Induction of potent CD4+ T cell-mediated antitumor responses by a helper HER-2/neu peptide linked to the Ii-Key moiety of the invariant chain
Ioannis F. Voutsas et al.
INTERNATIONAL JOURNAL OF CANCER (2007)
Preoperative plasma HER2 and epidermal growth factor receptor for staging and prognostication in patients with clinically localized prostate cancer
Shahrokh F. Shariat et al.
CLINICAL CANCER RESEARCH (2007)
Ii-Key/HER-2/neu(776-790) hybrid peptides induce more effective immunological responses over the native peptide in lymphocyte cultures from patients with HER-2/neu+ tumors
Nectaria N. Sotiriadou et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2007)
Pretreatment serum level of HER2/nue as a prognostic factor in metastatic prostate cancer patients about to undergo endocrine therapy
Takatsugu Okegawa et al.
INTERNATIONAL JOURNAL OF UROLOGY (2006)
Androgen-dependent regulation of Her-2/neu in prostate cancer cells
Raanan Berger et al.
CANCER RESEARCH (2006)
Interferon-γ renders tumors that express low levels of Her-2/neu sensitive to cytotoxic T cells
BLF Kaplan et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2006)
Molecular alterations associated with LNCaP cell progression to androgen independence
XB Shi et al.
PROSTATE (2004)
Her-2/neu expression in prostate cancer: A dynamic process?
J Carles et al.
CLINICAL CANCER RESEARCH (2004)
Small interfering RNA (siRNA) inhibits the expression of the Her2/neu gene, upregulates HLA class I and induces apoptosis of Her2/neu positive tumor cell lines
A Choudhury et al.
INTERNATIONAL JOURNAL OF CANCER (2004)
HER-2/neu-mediated regulation of components of the MHC class I antigen-processing pathway
F Herrmann et al.
CANCER RESEARCH (2004)
HER2/neu kinase-dependent modulation of androgen receptor function through effects on DNA binding and stability
IK Mellinghoff et al.
CANCER CELL (2004)
Ii-Key/HER-2/neu MHC class-II antigenic epitope vaccine peptide for breast cancer
ME Gillogly et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2004)
Evaluation of HER-2/neu expression in prostatic adenocarcinoma -: A request for a standardized, organ specific methodology
KM Sanchez et al.
CANCER (2002)
HER2 expression in prostatic cancer: A comparison with mammary carcinoma
M Jorda et al.
JOURNAL OF UROLOGY (2002)
Peptide HER2(776-788) represents a naturally processed broad MHC class II-restricted T cell epitope
R Sotiriadou et al.
BRITISH JOURNAL OF CANCER (2001)
Her-2-neu expression and progression toward androgen independence in human prostate cancer
S Signoretti et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2000)
分享论文
